Demographic characteristics and clinical features of patients with AS and healthy controls. Data are mean ± SD unless otherwise indicated.
| Variables | AS, n = 362 | Controls, n = 362 |
|---|---|---|
| Age, yrs | 41.9 ± 11.0 | 42.9 ± 11.1 |
| Male (%) | 251 (69.3) | 251 (69.3) |
| Family history of AS (%) | 158 (43.6) | |
| Clinical features | ||
| Age at symptom onset, yrs | 30.2 ± 12.5 | |
| Disease duration, yrs | 11.8 ± 10.1 | |
| Delayed diagnosis, yrs | 5.7 ± 7.3 | |
| Peripheral arthritis (%) | 174 (48.1) | |
| Uveitis (%) | 98 (27.1) | |
| Psoriasis (%) | 47 (13.0) | |
| Inflammatory bowel disease (%) | 18 (5.0) | |
| Laboratory results | ||
| HLA-B27-positive | 334 (92.3%) | |
| ESR, mm/h | 25.1 ± 19.1 | |
| CRP, mg/dl | 1.2 ± 1.8 | |
| IgA, mg/dl | 327.1 ± 176.4 | |
| BASDAI, cm | 4.1 ± 2.3 | |
| BASFI, cm | 2.3 ± 2.3 | |
| BAS-G, cm | 4.5 ± 2.8 | |
| Medication history | ||
| NSAID use (%) | 192 (53.0) | |
| DMARD use (%) | 107 (29.6) |
AS: ankylosing spondylitis; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; BAS-G: Bath Ankylosing Spondylitis Global; NSAID: nonsteroidal antiinflammatory drug; DMARD: disease-modifying antirheumatic drug.